BioNTech SE (BNTX) — Quality & forensics

As of 2026-08-06 — refreshed nightly. Closelook readings from an investment research diary, not ratings or advice.

The Closelook module scores

34 /100 composite · 7 modules · general weight set

Valuation 55
Quality 26
Growth 5
Balance sheet 52
Cash quality 70
Capital allocation 21
Momentum 31

Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.

Financial forensics — the academic screens

6.91 Altman Z-Score

Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.

5/9 Piotroski F-Score

Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.

-3.09 Beneish M-Score

Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.

Continue: the BNTX chart & overview

FAQ · from the current data · as of 2026-08-06

Quick answers

What is BioNTech SE's Closelook quality reading?

The composite reads 34/100 across 7 modules, as of 2026-08-06: valuation 55, quality 26, growth 5, balance sheet 52, cash quality 70, capital allocation 21, momentum 31. Closelook scores are research diary readings, not ratings or investment advice.

What is BioNTech SE's Altman Z-Score?

6.91, which sits in the safe zone (above 2.99) as of 2026-08-06. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.

What is BioNTech SE's Piotroski F-Score?

5 of 9, as of 2026-08-06. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.

What does BioNTech SE's Beneish M-Score indicate?

-3.09 — below the −1.78 manipulation-risk threshold, as of 2026-08-06. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.